Sponsors

Reducing exposure to antimicrobial agents

More people die each year from sepsis than cancers of the breast and prostate, and human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) combined. An initiative by the biochemistry laboratory at Portsmouth’s Queen Alexandra Hospital is designed to explore ways of reducing the impact of such life-threatening infections.

Procalcitonin (PCT), a prohormone of calcitonin, is an inflammatory marker with a high specificity for bacterial infection. It has been observed as a useful adjunct in determining whether or not a patient has sepsis. With regard to antimicrobial stewardship, a negative procalcitonin result is a point of reassurance to support the cessation of antibiotic treatment, reducing unnecessary associated costs and side-effects.

The Portsmouth laboratory is collaborating with Beckman Coulter Diagnostics on a study that measures the effectiveness of the company’s new CE-marked Access PCT assay.  The laboratory’s long-term objective is to spearhead new protocols for speeding up appropriate treatment of sepsis with antibiotics within the hospital, placing particular emphasis on patient safety. 

 

See more about Beckman Coulter UK Ltd

Latest Issues

UK NEQAS for Microbiology & Parasitology Annual Scientific Meeting 2026

The Royal National Hotel, 38 – 51 Bedford Way, London, WC1H 0DG
27 November 2026

UK NEQAS webinar: Epigenetics

Online
1 December 2026

Weqas Annual POCT Conference 2026

London Hilton Heathrow Airport Terminal 5, Heathrow
8-9 December 2026